Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
  • Patent number: 10844127
    Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 24, 2020
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robertus Cornelis Roovers
  • Patent number: 10836830
    Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: November 17, 2020
    Assignees: AGENUS INC., MEMORIAL SLOAN-KETTERING CANCER CENTER, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: Nicholas S. Wilson, Jeremy D. Waight, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Ekaterina V. Breous-Nystrom, Volker Seibert, Takemasa Tsuji, Olivier Léger, Dennis J. Underwood, Marc Van Dijk
  • Patent number: 10835593
    Abstract: Disclosed is a Bacillus anthracis protective antigen (PA) comprising a PA amino acid sequence, wherein one or more of amino acid residues I207, I210, E654, I656, R659, M662, Y681, and L687, as defined by reference to SEQ ID NO: 1, are, independently, substituted, with the proviso that amino acid residue I207 is not substituted with alanine and amino acid residue I210 is not substituted with alanine. Related compositions, nucleic acids, recombinant expression vectors, host cells, populations of cells, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 17, 2020
    Assignee: The United States of America as represented by the Secretary Department of Health and Human Services
    Inventors: Shi-Hui Liu, Stephen H. Leppla, Thomas H. Bugge, Alexander N. Wein, Diane E. Peters, Jie Liu, Kuang-Hua Chen
  • Patent number: 10815534
    Abstract: This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A?G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 27, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Tanda T. Dudenkov, Liewei Wang, James N. Ingle, Richard M. Weinshilboum, Junmei Cairns
  • Patent number: 10808029
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: October 20, 2020
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
  • Patent number: 10806771
    Abstract: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: October 20, 2020
    Assignee: BIOINCEPT, LLC
    Inventor: Eytan R. Barnea
  • Patent number: 10774119
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: September 15, 2020
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Marlon Hinner, Alexander Wiedenmann, Andrea Allersdorfer
  • Patent number: 10766959
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: September 8, 2020
    Assignee: Pierre Fabre Medicament
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • Patent number: 10724014
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: July 28, 2020
    Assignees: Institut National de la Sante et de la Recherche Medicale, Université Paul Sabatier Toulouse III
    Inventor: Elvire Gouze
  • Patent number: 10722578
    Abstract: Methods and compositions for treating neuroblastoma are disclosed.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: July 28, 2020
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Yael P. Mosse, Erica L. Carpenter
  • Patent number: 10717778
    Abstract: The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: July 21, 2020
    Assignees: DUKE UNIVERSITY, MACROGENICS, INC., THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Barton F. Haynes, Guido Ferrari, Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Julia A. Sung, David M. Margolis, Liqin Liu, Jeffrey Lee Nordstrom
  • Patent number: 10646567
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: May 12, 2020
    Assignee: Genentech, Inc.
    Inventors: Heather Maecker, Bryan Irving
  • Patent number: 10639368
    Abstract: The instant disclosure provides antibodies that specifically bind to TIM-3 (e.g., human TIM-3) and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: May 5, 2020
    Assignee: AGENUS INC.
    Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
  • Patent number: 10640777
    Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 5, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PANGEN BIOTECH INC.
    Inventors: Do Hyun Nam, Yong Jae Shin, Jae Hyun Lee
  • Patent number: 10640564
    Abstract: The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: May 5, 2020
    Assignee: Ichnos Sciences SA
    Inventors: Rami Lissilaa, Adrian Walmsley, Stanislas Blein, Romain Ollier, Samuel Hou, Jeremy Loyau
  • Patent number: 10626170
    Abstract: Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such antibodies, both active and passive, and methods for identifying antibodies specific for sulfonation sites in Sclerostin and other antibodies which discriminate between sulfonated and unsulfonated forms of sclerostin. Physical and virtual screening processes are provided in this invention for identifying compounds which disrupt or inhibit sulfonation and the interaction between Sclerostin and binding partners. The antibodies and compositions of the present invention are useful in diagnostic and therapeutic applications directed to Sclerostin-related disorders.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 21, 2020
    Assignee: Enzo Biochem, Inc.
    Inventor: Joshua Rabbani
  • Patent number: 10610592
    Abstract: A composition for treating neurodegeneration, including an antibiotic, an antifungal agent, and a lipophilic potentiating agent in synergistically effective amounts. A method of treating neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and treating neurodegeneration. A method of reducing and/or eliminating symptoms of neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and reducing and/or eliminating the individual's symptoms of neurodegeneration. A method of reducing and/or eliminating lesions from neurodegeneration. A method of recovering mobility of an individual suffering from neurodegeneration.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 7, 2020
    Inventor: Fabrizio De Silvestri
  • Patent number: 10611846
    Abstract: The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: April 7, 2020
    Assignee: ZymoGenetics, Inc.
    Inventor: Janine M. Bilsborough
  • Patent number: 10611850
    Abstract: Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 7, 2020
    Assignee: Amgen Inc.
    Inventors: Twinkle R. Christian, Christi L. Clogston, Timothy David Osslund
  • Patent number: 10604572
    Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 31, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PANGEN BIOTECH INC.
    Inventors: Do Hyun Nam, Yong Jae Shin, Jae Hyun Lee
  • Patent number: 10604571
    Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 31, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PANGEN BIOTECH INC.
    Inventors: Do Hyun Nam, Yong Jae Shin, Jae Hyun Lee
  • Patent number: 10570204
    Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA-4. In one embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of TIM-3. In another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of LAG-3. In yet another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of CTLA-4.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: February 25, 2020
    Assignees: The Medical College of Wisconsin, Inc., Novartis AG
    Inventors: Bryon Duane Johnson, Robert Millman
  • Patent number: 10563265
    Abstract: Disclosed are a novel method of detecting cancer, a method of screening inhibitors and anticancer agents that target cancer-related molecules, RHOA polypeptide having mutation and a polynucleotide encoding the polypeptide as a therapeutic agent for cancer, and a method of detecting cancer using the polypeptide or polynucleotide. Also disclosed are a vector and a host cell comprising the polynucleotide, a method of screening therapeutic agents for cancer comprising the polypeptide and/or the polynucleotide, and a therapeutic agent for cancer comprising siRNA having a silencing effect on RHOA mutant.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: February 18, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Aburatani, Shumpei Ishikawa, Miwako Kakiuchi, Takashi Nishizawa
  • Patent number: 10561706
    Abstract: The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject. The composition a peptide derived from SOD1 which can be used to inhibit formation of SOD1 amyloid-like aggregates or for production of anti-SOD1 antibodies.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: February 18, 2020
    Assignee: B. G. NEGEV TECHNOLOGIES AND APPLICATIONS
    Inventor: Stanislav Engel
  • Patent number: 10550160
    Abstract: Described herein are methods and compositions relating to engineered curli fibers, e.g. CsgA polypeptide. In some embodiments, the methods and compositions described herein relate to functionalized biofilms.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: February 4, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Neel Satish Joshi, Peter Q. Nguyen, Zsofia Magarian
  • Patent number: 10544227
    Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: January 28, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Akihisa Kaneko, Yuki Iwayanagi, Hidetomo Kitamura, Yoshinobu Higuchi, Hiroaki Matsushita, Ryosuke Mihara, Yumi Yamamoto, Tomohisa Saito, Keiko Hirokawa
  • Patent number: 10538582
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: January 21, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Patent number: 10533036
    Abstract: It is described a Clostridium difficile (C-difficile) toxins A and/or B as a target for therapy, including passive immunotherapy, and particularly prevention of C-difficile intoxication in human or other animals. It is also described a polypeptide comprising a portion of C-difficile toxins A and/or B sequence being an epitope for anti-toxins A and/or B antibody. It is also disclosed a method for generating a neutralizing antibody directed against C-difficile toxins A and/or B. It is also provided a novel formulation that combines key toxins A and/or B epitope antibodies, located in three key domains of toxins A and/or B, for neutralizing toxins A and/or B, at any stage of toxins A and/or B intoxication related to C-difficile infection. The novel formulation of toxins A and/or B epitope antibodies are useful in immunotherapy, for therapeutic and/or prophylactic mediation of C-difficile intoxication.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: January 14, 2020
    Assignee: IMMUNE BIOSOLUTIONS INC
    Inventors: Simon Gaudreau, Martin Cloutier, Louis-Charles Fortier, Frederic Leduc, Maxime Tremblay, Steeve Veronneau, Djorjde Gbric, Jean-Francois Larrivee
  • Patent number: 10513557
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 24, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
  • Patent number: 10478496
    Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: November 19, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Chigusa Yoshimura, Reimi Kawaida, Kokichi Honda
  • Patent number: 10471143
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: November 12, 2019
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith
  • Patent number: 10465004
    Abstract: The invention provides antibodies or an antigen-binding portion thereof, which recognize the human Frizzled 7 receptor. Further, the invention provides methods of using these antibodies for the treatment cancer in a subject.
    Type: Grant
    Filed: January 1, 2015
    Date of Patent: November 5, 2019
    Assignees: Tel HaShomer Medical Research Infrastructure and Services Ltd., Ramot at Tel-Aviv University Ltd.
    Inventors: Benjamin Dekel, Naomi Pode-Shakked, Orit Harai-Steinberg, Michal Mark-Danieli, Einav Vax
  • Patent number: 10457739
    Abstract: Antibodies are provided which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also provided are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising the antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: October 29, 2019
    Assignee: SANOFI
    Inventors: Pierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
  • Patent number: 10449543
    Abstract: A system and method for isolating and analyzing single cells, comprising: a substrate having a broad surface; a set of wells defined at the broad surface of the substrate, and a set of channels, defined by the wall, that fluidly couple each well to at least one adjacent well in the set of wells; and fluid delivery module defining an inlet and comprising a plate, removably coupled to the substrate, the plate defining a recessed region fluidly connected to the inlet and facing the broad surface of the substrate, the fluid delivery module comprising a cell capture mode.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 22, 2019
    Assignee: Celsee Diagnostics, Inc.
    Inventors: Kalyan Handique, Priyadarshini Gogoi, Saedeh Javdani Sepehri, Kyle Gleason
  • Patent number: 10435477
    Abstract: Provided herein is a proprotein convertase subtilisin kexin type 9 (PCSK9)-specific binding protein that comprises unique complementary determining regions, that is capable of specifically binding to PCSK9, effectively inhibiting the function of PCSK9, lowering plasma LDL cholesterol level and that is useful in treating diseases associated with or impacted by the function of PCSK9.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: October 8, 2019
    Inventor: Shaoxiong Wang
  • Patent number: 10428312
    Abstract: An antibody that binds a glycosylated protein is disclosed, wherein the glycosylation comprises the glycan motif Fuc?1-2Gal?1-3GlcNAc1-3Gal?1 or Fuc?1-2Gal?1-3GlcNAc. Antibodies that are cytotoxic against undifferentiated pluripotent cells are also disclosed.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: October 1, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Boon Hwa Andre Choo, Jiyun Zheng
  • Patent number: 10421807
    Abstract: A cell-based assay for assessing the functional activity of a canine or feline IL-31 inhibitor candidate is provided. Such a canine or feline IL-31 inhibitor candidate can be an isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: September 24, 2019
    Assignee: Zoetis Services LLC
    Inventors: Andrea Joy Gonzales, Gregory Fici, Gary Francis Bammert, Steven Alan Dunham
  • Patent number: 10421962
    Abstract: Provided herein are double stranded nucleic acid molecules, compositions comprising same and methods of use thereof for the treatment of a subject wherein expression of DDIT4 is associated with the etiology or progression of a disease or disorder in the subject. The compounds are preferably chemically synthesized and modified dsRNA molecules.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: September 24, 2019
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
  • Patent number: 10413591
    Abstract: Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: September 17, 2019
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: S. Ananth Karumanchi, Vikas P. Sukhatme
  • Patent number: 10365282
    Abstract: A method for assessing sarcoma metastasis comprising obtaining a biological sample of the subject, detecting a level of a N-terminal segment of moesin in the biological sample, wherein the level of the N-terminal segment of moesin detected in the biological sample of the subject is indicative of the subject developing or with an increased probability of developing metastasis of sarcoma. The present application also provides a biomarker and a kit for assessing metastasis of sarcoma, and uses of such biomarker. The present application also provides a method of treating sarcoma metastasis.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: July 30, 2019
    Assignee: SHANGHAI KEXIN BIOTECH CO., LTD.
    Inventors: Yue Zhang, Jun Bao
  • Patent number: 10364295
    Abstract: Purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences are provided.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: July 30, 2019
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Patent number: 10358485
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: July 23, 2019
    Assignees: Eisai R&D Management Co., Ltd., UCL Business PLC
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Patent number: 10350294
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 16, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Patent number: 10351852
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: July 16, 2019
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: James McSwiggen, Leonid Beigelman, Chandra Vargeese
  • Patent number: 10344283
    Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: July 9, 2019
    Assignee: Research Foundation of the City University of New York
    Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
  • Patent number: 10316099
    Abstract: The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of toxicity of A? oligomers. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of Alzheimer's Disease. The invention also relates to methods of medical treatment.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 11, 2019
    Assignee: D-GEN LIMITED
    Inventors: John Collinge, Andrew J Nicoll
  • Patent number: 10307487
    Abstract: Disclosed herein are microvessel endothelial cell surface markers and methods, compositions, agents, and kits relating to those surface markers.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: June 4, 2019
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital
    Inventors: Ulrich H. von Andrian, Aude Thiriot, Omid Farokhzad, Jinjun Shi
  • Patent number: 10301379
    Abstract: The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: May 28, 2019
    Assignee: JANSSEN VACCINES & PREVENTION B.V.
    Inventors: Jehangir Wadia, Gabriel Pascual, Robert Anthony Williamson, Katarina Radosevic, Jaap Goudsmit
  • Patent number: 10301362
    Abstract: A method and composition for eliciting an immune response to group A streptococcal bacteria in a mammal is provided, which includes administering to the mammal an M protein fragment, variant or derivative thereof and a SpyCEP protein or peptide fragment, or an antibody to the SpyCEP protein or fragment to facilitate restoring or enhancing neutrophil activity. Also provided is an immunodominant peptide fragment of SpyCEP.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: May 28, 2019
    Assignee: Griffith University
    Inventors: Manisha Pandey, Michael Batzloff, Michael Good
  • Patent number: 10294300
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: May 21, 2019
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek